Home/ Stocks/ JANX

Janux Therapeutics, Inc. Common Stock

JANX XNAS

$15.85 -0.25 (-1.55%) ▼ 15-min delayed

Open

$15.73

High

$16.19

Low

$15.73

Volume

689.0K

Market Cap

$981.85M

About Janux Therapeutics, Inc. Common Stock

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 108 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$3.73M	$-24,361,000	$-0.39
FY 2025	$10.00M	$-113,625,000	$-1.83
Q3 2025	$10.00M	$-24,313,000	$-0.39
Q2 2025	$0	$-33,858,000	$-0.55

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for JANX yet. Check out our latest market news or earnings calendar.

Get JANX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Janux Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.